Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib + Chemotherapy in Newly Diagnosed AML
NCT02236013Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2015
- Primary completion
- Jul 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of gilteritinib in acute myeloid leukemia (AML) (4 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities up to 2.5 years, Maximum Tolerated Dose up to 2.5 years and 1 more. Started Jan 2015; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02236013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236013.